Monitoring and evaluation workshops
WHO has carried out a series of workshops in monitoring and evaluating drug resistance in antimalarial drugs.
Fourteen participants from Afghanistan, Djibouti, Islamic Republic of Iran, Republic of Yemen, Saudi Arabia, Somalia and Sudan attended this workshop.
- To review the situation of resistance to antimalarial drugs.
- To introduce WHO protocols for the assessment of the therapeutic efficacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in areas with intense transmission and with low/moderate transmission.
- To present the role of in vitro tests and current methods for detection of molecular markers in the surveillance of resistance to antimalarial drugs.
- To define the technical and operational aspects for strengthening surveillance of drug resistance of falciparum malaria at the country level.
Interregional workshop on strengthening national and regional capacities in surveillance of antimalarial drug resistance: Lyon, France, 25 - 29 June 2001
Objectives: At the end of the workshop the participants:
- Would be able to carry out a field survey to assess therapeutic efficacy of an antimalarial treatment in a given patient population according to WHO guidelines.
- Would be able to classify, present and analyse the results using the appropriate software.
- Would be able to interpret the results in relation to antimalarial drug policy and use in relation to further research needs.
- Have knowledge of the details of the in vitro techniques required for assessing antimalarial drug susceptibility, their advantages and limitations in relation to in vivo testing, and their role in public health.
A WHO-supported workshop on monitoring treatment efficacy of antimalarial drug resistance. Bangkok, Thailand, 27-30 March 2001. Twenty-seven participants from 8 countries from South-East Asia and Western Pacific countries attended this workshop.
The workshop was facilitated by WHO, ACTMalaria, an intercountry initiative between Bangladesh, Cambodia, China (Yunnan Province), Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Thailand, and Vietnam that aims to collect, develop, and disseminate training materials; to implement practical training courses to meet the needs of malaria control programmes in South-East Asia and the Mekong Valley; and to improve communication between the member countries on malaria control problems affecting their common borders; and SEAMEO-TROPMED, the Southeast Asian Ministers of Education Organization, founded to promote regional cooperation among Southeast Asian nations, through education, science (tropical medicine) and culture.
WHO is providing support to many countries so they can monitor the efficacy of antimalarial drugs or combination therapies for the treatment of falciparum or vivax malaria. This support has been given to participants from ministries of health, national research and educational institutions and national specialists in malaria in:
- WHO Region for the Americas: Monitoring the efficacy of first- and second-line drugs for the treatment of falciparum and vivax malaria: Colombia, Bolivia, Brazil, Ecuador, Venezuela
- WHO Region for South-East Asia:
- Monitoring the efficacy of first- and second-line drugs for the treatment of falciparum malaria: Bangladesh, India, Indonesia, Myanmar, Nepal, Sri Lanka
- Monitoring the efficacy of alternative treatment against chloroquine-resistant vivax malaria: Indonesia
- WHO Region for Africa: Monitoring the efficacy of combination therapy with artemisinin derivatives for the treatment of falciparum malaria: Ghana and Rwanda
- WHO Region for Europe:
- Monitoring the efficacy of chloroquine for the treatment of vivax malaria:Azerbaijan, Tajikistan and Turkey
- Monitoring the efficacy of first- and second-line drugs for the treatment of falciparum malaria:Tajikistan
- WHO Region for the Eastern Mediterranean: Monitoring the efficacy of first and second line drugs for the treatment of falciparum malaria: Islamic Republic of Iran, Republic of Yemen, Somalia, Sudan.
Find out more about WHO's work in Roll Back Malaria